Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial)Pim Hendriks, Daphne D. D. Rietbergen, Arian R. van Erkel et al.|European Journal of Nuclear Medicine and Molecular Imaging|2024Cited by 8
The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated CirrhosisLukas Hartl, Thomas Reiberger, Marlene Hintersteininger et al.|Clinical Gastroenterology and Hepatology|2025Cited by 6
Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients—A Dose-Finding Study (HORA EST HCC Trial)Pim Hendriks, Daphne D. D. Rietbergen, Arian R. van Erkel et al.|CardioVascular and Interventional Radiology|2022Cited by 4
Secretory <scp>IgA</scp> Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in <scp>ACLF</scp>Boglárka Balogh, Mária Papp, Dávid Tornai et al.|Liver International|2025Cited by 4
Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and ValidationDávid Tornai, Mária Papp, Minneke J. Coenraad et al.|Alimentary Pharmacology & Therapeutics|2025Cited by 4